Serotonergic drugs and movement disorders in humans

Drugs of Today

Volumn 33, Issue 6, 1997, Pages 379-392

  Pranzatelli, Michael R ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b National Pediatric Myoclonus Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; BUSPIRONE; CISAPRIDE; CLOMIPRAMINE; CYPROHEPTADINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; LISURIDE; METHYSERGIDE; METOCLOPRAMIDE; ONDANSETRON; PAROXETINE; PROPRANOLOL; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SERTRALINE; SUMATRIPTAN; TRAZODONE;

ATTENTION DEFICIT DISORDER; DRUG STRUCTURE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MOTOR DYSFUNCTION; MYOCLONUS; PARKINSON DISEASE; REVIEW; SEROTONINERGIC SYSTEM; TREMOR;

EID: 0030839476     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Rapport, M.M., Green, A.A., Page, I.H. Purification of the substance which is responsible for vasoconstrictor activity of serum. Fed Proc 1947, 6: 184.
2. Pranzatelli, M.R. The proposed role of neurotransmitter receptors in the pathophysiology of human myoclonic disorders. Med Hypotheses 1989, 30: 55-60.
3. Hartig, P.R., Kao, H.T., Macchi, M. et al. The molecular biology of serotonin receptors: An overview. Neuropsychopharmacology 1990, 3: 335-47.
4. 2 receptor subtypes: A family re-united? Trends Pharmacol Sci 1995, 6: 105-10.
5. Bradley, P.B., Engel, G., Feniuk, W. et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986, 6: 563-76.
6. 4 receptor: Naughty, but nice. Trends Pharmacol Sci 1989, 10: 385-6.
7. Erlander, M.G., Lovenberg, T.W., Baron, B.M. et al. Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc Natl Acad Sci USA 1993, 90: 3452-6.
8. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993, 11: 449-58.
9. Meyerhof, W., Obermuller, F., Fehr, S., Richter, D. A novel rat serotonin receptor: Primary structure, pharmacology, and expression patterns in distinct brain regions. DNA Cell Biol 1993, 12: 401-9.
10. 3 receptors: Pharmacologic and therapeutic aspects. J Clin Pharmacol 1995, 35: 845-55.
11. Cakey, R.J., Caron, M.G., Lefkowitz, R.J., Seldin, M.F. Genomic organization of adrenergic and serotonin receptors in the mouse: Linkage mapping of sequence related genes provides a method for examining mammalian chromosome evolution. Genomics 1991, 10: 338-44.
12. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 1993, 90: 408-12.
13. 1A receptor. Nature 1988, 335: 358-60.
14. 2 receptor clone. Soc Neurosci Abstr 1989, 15: 486.
15. 1B receptor. J Biol Chem 1992, 267: 5735-8.
16. 5B receptors define a new family of serotonin receptors: Cloning, functional expression, and chromosomal localization. Mol Pharmacol 1993, 43: 313-9.
17. 1E receptor. Mol Pharmacol 1992, 42: 180-5.
18. 1D receptor subtype. Mol Pharmacol 1992, 42: 439-44.
19. Shen, Y., Monsma, F.J., Metcalf, M.A., Jose, P.A., Hamblin, M.W., Sibley, D.R. Molecular cloning and expression of a 5-hydroxytryptamine serotonin receptor subtype. J Biol Chem 1993, 268: 18200-4.
20. 6) receptor: Molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993, 193: 268-76.
21. 7) activating cAMP formation. Proc Natl Acad Sci USA 1993, 90: 8547-51.
22. Monsma, F.J., Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993, 43: 320-2.
23. Saudou, F., Hen, R. 5-Hydroxytryptamine receptor subtypes: Molecular and functional diversity. Adv Pharmacol 1994, 30: 327-80.
24. Hsieh, C.-L., Bowcock, A.M., Farrer, L.A. et al. The serotonin receptor subtype 2 locus HTRZ is on human chromosome 13 near genes for esterase D and retinoblastoma-1 and on mouse chromosome 14. Somat Cell Mol Genet 1990, 16: 567-74.
25. Sparkes, R.S., Lan, N., Klisak, I. et al. Assignment of a serotonin 5HT-2 receptor gene (HTRZ) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics 1991, 9: 461-5.
26. Gozlan, H., El Mestikawy, S., Pichat, L., Glowinski, J., Hamon, M. Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature 1983, 7: 140-2.
27. Glennon, R.A. Central serotonin receptors as targets for drug research. J Med Chem 1987, 30: 1-12.
28. 2 immuno-reactive neurons in the rat brain. Soc Neurosci Abstr 1992, 18: 212.
29. 2 presynaptic receptors mediate inhibition of glutamate release from cerebellar mossy fibre terminals. Eur J Pharmacol 1991, 202: 185-90.
30. Pazos, A., Probst, A., Palacios, J.M. Serotonin receptors in the human brain. III: Autoradiographic mapping of serotonin-1 receptors. Neuroscience 1987, 21: 97-122.
31. 1D) in the human brain by autoradiography. Neurosci Lett 1988, 88: 11-6.
32. 1B serotonin receptor: Cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci USA 1992, 89: 3020-4.
33. 1B recognition sites. Brain Res 1986, 376: 85-96.
34. 2 recognition sites. Brain Res 1986, 376: 97-107.
35. Pazos, A., Probst, A., Palacios, J.M. Serotonin receptors in the human brain. IV: Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987, 21: 123-39.
36. 2-receptors in human brain. Brain Res 1983, 276: 231-5.
37. 1-like receptors in rat brainstem neurones. Br J Pharmacol 1988, 94: 492-9.
38. 2-like receptors on rat brainstem neurones. Br J Pharmacol 1988, 94: 483-91.
39. 3 recognition sites within the human brainstem. Neurosci Lett 1990, 111: 80-6.
40. Magnussen, I., Mondrup, K., Engbaek, F., Lademann, A., DeFine Olivarius, B. Treatment of myoclonic syndromes with paroxetine alone or combined with 5-HTP. Acta Neurol Scand 1982, 66: 276-82.
41. Van Woert, M.H., Magnussen, I., Rosenbaum, D., Chung, E. Fluoxetine in the treatment of intention myoclonus. Clin Neuropharmacol 1983, 6: 49-54.
42. 1C receptor activity. Soc Neurosci Abstr 1992, 18: 1522.
43. Caccia, S., Fong, M.H., Garattinis, V., Zanini, M.G. Plasma concentrations of trazodone and 1-(3-chlorophenyl)piperazine in man after a single dose of trazodone. J Pharm Pharmacol 1982, 34: 605-6.
44. Edwards, E., Whitaker-Azmitia, P.M. Selective β-antagonists are equally and highly potent at 5-HT sites in the rat hippocampus. Neuropharmacology 1987, 26: 93-6.
45. 2 receptors. J Pharmacol Exp Ther 1993, 266: 1374-84.
46. 1C sites. Eur J Pharmacol 1990, 191: 93-6.
47. Pranzatelli, M.R., Snodgrass, S.R. The pharmacology of myoclonus. Clin Neuropharmacol 1985, 8: 99-130.
48. Pranzatelli, M.R. Effect of chronic treatment with 5-hydroxytryptophan on cortical serotonin receptors in the rat. Clin Neuropharmacol 1988, 11: 257-62.
49. Pranzatelli, M.R. Serotonin and human myoclonus: Rationale for the use of serotonin receptor agonists and antagonists. Arch Neurol 1994, 51: 605-17.
50. 2 receptor mRNA levels. Eur J Pharmacol 1991, 207: 169-72.
51. 12 subunit mRNA expression in rat brain. Eur J Pharmacol 1992, 227: 233-7.
52. Cross, A.J., Crow, T.J., Ferrier, I.N. et al. Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 1984, 43: 1574-81.
53. 2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy. Mov Disord 1988, 3: 255-62.
54. 1A Receptors. Dourish, C.T., Ahlenius, S., Hutson, P.H. (Eds.). Ellis Harwood; New York 1987, 286-99.
55. 2 receptor binding abnormalities in patients with Alzheimer's disease: Comparisons with Parkinson's disease. Neurosci Lett 1984, 51: 353-7.
56. 3H-paroxetine binding sites in putamen. Neurology 1986, 36: 556-60.
57. 2 receptors in senile dementia of the Alzheimer type. Neurosci Lett 1984, 44: 47-51.
58. Bodner, R.A., Lynch, T., Lewis, L., Kahn, D. Serotonin syndrome. Neurology 1995, 45: 219-23.
59. Nijhawan, P.K., Katz, G., Winter, S. Psychiatric illness and the serotonin syndrome: An emerging adverse drug effect leading to intensive care unit admission. Crit Care Med 1996, 24: 1086-9.
60. Sajatovic, M., Meltzer, H.Y. Clozapine-induced myoclonus and generalized seizures. Biol Psychiatry 1996, 39: 367-70.
61. Goldberg, R.J., Huk, M. Serotonin syndrome from trazodone and buspirone. Psychsomatics 1992, 33: 235-6.
62. Lappin, R., Auchincloss, E. Treatment of the serotonin syndrome with cyproheptadine. New Engl J Med 1994, 331: 1021-2.
63. Sandyk, R. L-Dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol 1986, 6: 194-5.
64. Guze, B.H., Baxter, L.R. The serotonin syndrome: Case reponsive to propranolol. J Clin Psychpharmacol 1986, 6: 119-20.
65. Hyser, C.L., Drake, M.E. Myoclonus induced by metoclopramide therapy. Arch Intern Med 1983, 143: 2201-2.
66. Ludwig, C.L., Weinberger, D.R., Bruno, G. et al. Buspirone, Parkinson's disease and locus ceruleus. Clin Neuropharmacol 1986, 9: 373-8.
67. Bharucha, K.J., Sethi, K.D. Complex movement disorders induced by fluoxetine. Mov Disord 1996, 11: 324-6.
68. Bouchard, R.H., Poucher, E., Vincent, P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989, 146: 1352-3.
69. Arya, D.K. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994, 165: 728-33.
70. Chen, J., Paredes, W., Van Praag, H.M. et al. Serotonin denervation enhances responsiveness of presynaptic dopamine efflux to acute clozapine in nucleus accumbens but not in caudate-putamen. Brain Res 1992, 582: 173-9.
71. Shulman, L.M., Singer, C., Weiner, W. Risperidone in Gilles de la Tourette syndrome. Neurology 1995, 45: 1419.
72. Bruun, R.D., Budman, C.L. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996, 57: 29-31.
73. Dursun, S.M., Burke, J.G., Reveley, M.A. Buspirone treatment of Tourette's syndrome. Lancet 1995, 345: 1366-7.
74. Brasic, J.R., Barnett, J.Y., Kaplan, D. et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 1994, 44: 1309-12.
75. Spencer, T., Biederman, J., Wilens, T. Tricyclic antidepressant treatment of children with ADHD and tic disorders. J Am Acad Child Adolesc Psychiatry 1994, 33: 1203-4.
76. Barrickman, L.L., Perry, P.L., Allen, A.J. et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995, 34: 649-57.
77. Kaye, J.A., May, C., Atack, J.R. et al. Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Ann Neurol 1988, 24: 647-50.
78. Leino, E., MacDonald, E., Airaksinen, M.M., Riekkinen, P.J. Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with progressive myoclonus epilepsy. Acta Neurol Scand 1980, 62: 41-54.
79. Guilleminault, C., Tharp, B.R., Cousin, D. HVA and 5-HIAA CSF measurements and 5-HTP trials in some patients with involuntary movements. J Neurol Sci 1973, 18: 435-41.
80. Koskiniemi, M., Hyppa, M., Sainio, K., Salmi, T., Sarna, S., Uotila, L. Transient effect of L-tryptophan in progressive myoclonus epilepsy without Lafora bodies: Clinical and electrophysiological study. Epilepsia 1980, 21: 351-7.
81. Leino, E., MacDonald, E., Airaksinen, M.M., Riekkinen, P.J., Sale, H. L-Tryptophan carbidopa trial in patients with long-standing progressive myoclonus epilepsy. Acta Neurol Scand 1981, 64: 132-41.
82. Centers for Disease Control. Eosinophilia-myalgia syndrome: New Mexico. MMWR Morb Mortal Wkly Rep 1989, 38: 765-7.
83. Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, E.H., Marsden, C.D. Clinical, biochemical and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor and clonazepam. Brain 1977, 100: 455-87.
84. DeLean, J., Richardson, J.C., Hornykiewicz, O. Beneficial effects of serotonin precursors in postanoxic action myoclonus. Neurology 1976, 26: 863-8.
85. Lhermitte, F., Marteau, R., Degos, C.F. Analyse pharmacologique d'un nouveau cas de myoclonies d'intention et d'action post-anoxique. Rev Neurol 1972, 126: 107-14.
86. Van Woert, M.H., Rosenbaum, D., Howieson, J., Bowers, M.B. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. New Engl J Med 1977, 296: 70-5.
87. Magnussen, E., Dupont, A., DeFine Olivarius, B. Palatal myoclonus treated with 5-hydroxytryptophan and a decarboxylase inhibitor. Acta Neurol Scand 1977, 55: 251-3.
88. Thai, L.J., Sharpless, N.S., Wolfson, L., Katzman, R. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: Clinical, electrophysiological, and biochemical observations. Ann Neurol 1980, 7: 570-6.
89. Pranzatelli, M.R., Tate, E., Huang, Y. et al. The neuropharmacology of progressive myoclonus epilepsy: Response to 5-hydroxy-L-tryptophan. Epilepsia 1995, 36: 783-91.
90. Gobbi, G., Melideo, G., Rossi, P.G. The effect of intravenous L-5-HTP in the myoclonic encephalopathy of infants. Neuropediatrics 1986, 17: 63-5.
91. Hashiba, Y., Kuroda, Y., Neshige, R., Shibasaki, H. A case of opsoclonus polymyoclonia syndrome: Suppression by TRH and 5-hydroxytryptophan. Rinsho Shinkeigaku 1984, 24: 1091-4.
92. Pranzatelli, M.R., Tate, E., Baldwin, M. Clinical responses to 5-hydroxy-L-tryptophan in chronic pediatric opsoclonus-myoclonus suggest biochemical heterogeneity: A double-blinded placebo crossover pilot study. Clin Neuropharmacol 1994, 17: 103-16.
93. Growdon, J.H., Young, R.R., Shahani, B.T. L-5-Hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. Neurology 1976, 26: 1135-40.
94. Obeso, J.A., Rothwell, J.C., Ouinn, N.P., Lang, A.E., Thompson, C., Marsden, C.D. Cortical reflex myoclonus responds to intravenous lisuride. Clin Neuropharmacol 1983, 6: 231-40.
95. Pranzatelli, M.R., Franz, D., Tate, E.D., Martens, J.M. Buspirone in progressive myoclonus epilepsy. J Neurol Neurosurg Psychiatry 1993, 56: 114-5.
96. Papini, M., Passquinelli, A., Filippini, A. Steroid-dependent form of Kinsbourne syndrome: Successful treatment with trazodone. Ital J Neurol Sci 1992, 13: 369-72.
97. Klawans, H.L., Goetz, C., Bergen, D. Levodopa-induced myoclonus. Arch Neurol 1975, 32: 331-4.
98. Carpentier, A.F., Bonnet, A.M., Vidailhet, M., Agid, Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996, 46: 1548-51.
99. Bonifati, V., Fabrizio, E., Cipriani, R. et al. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994, 17: 73-82.
100. Rabey, J.M., Treves, T.A., Neufeld, M.Y., Orlov, E., Korczyn, A.D. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995, 45: 432-4.
101. Zoldan, J., Friedberg, G., Goldberg-Stern, H., Melamed, E. Ondansetron for hallucinosis in advanced Parkinson's disease [letter]. Lancet 1993, 341: 562-3.
102. Bain, P.G., Findley, L.J., Thompson, P.D. et al. A study of hereditary essential tremor. Brain 1994, 117: 805-24.
103. Ferro, J.M., Calhan, E.S. Treatment of familial essential myoclonus with propranolol. Lancet 1977, 2: 143.
104. Koller, W.C., Hubble, J.P., Busenbark, K.L. Essential tremor. In: Neurodegenerative Diseases. Calne, D.B. (Ed.). WB Saunders: Philadelphia 1994, 717-42.